Search results
Showing: 10 of 661
Foreword from the Chief Executive
The coronavirus pandemic has been one of the most challenging periods in our lifetime and has required us to make some significant changes to the way we live and work to protect the health of our nation. Over this time, NHS Business Services…
General Pharmaceutical Services in England 2015/16 - 2021/22
Correction notice – Data for some advanced services were aggregated incorrectly resulting in inflated figures for this release
Read our correction notices page for full details.
Published 13 October 2022
Summary
Community pharmacies and…
Re-categorisation of Nutritional Borderline Substance (NBS) products – development and maintenance process
The NHS Business Services Authority (NHSBSA) has worked closely with the Department of Health and Social Care (DHSC) to improve the categorisation of NBS products. It is part of a system-wide move towards interoperability.
The work has been…
Prescription Cost Analysis – England – 2022-23
Correction notice - SNOMED codes in the national summary tables were incorrectly formatted.
Read our correction notices page for more details.
Published 8 June 2023
This page was last reviewed and updated 27 July 2023.
Summary
Prescription…
Prescribing for Diabetes – England – 2015/16 to 2022/23
Published 10 August 2023.
Summary
Diabetes features as one of the priorities for care and quality outcomes in the NHS Long Term Plan.
This publication aims to describe the prescribing of medicines and appliances, used for the treatment of…
Prescription Cost Analysis – England 2023/24
Published 6 June 2024.
Publication
Prescription Cost Analysis England 2023/24 - statistical summary narrative (HTML)
Summary
Prescription Cost Analysis (PCA) provides details of the costs and volumes of all prescriptions dispensed in the…
General Pharmaceutical Services in England 2015-16 - 2023-24
Misinterpreting active community pharmacies
We have been made aware that our headline figure for active community pharmacies can be misinterpreted. We would like to draw your attention to some important information for this figure.
When a…
Open and transparent
At the NHSBSA we are committed to being ’open by default’ when it comes to our data. This includes making our data and reporting open, where it is legal, appropriate, and safe to do so; being open about the data we hold, if and how it can be…
MO KTT
Access for:
registered users through ePACT2
public users through Catalyst
The charts and data tables show values for prescribing comparators supporting the quality, innovation, productivity and prevention (QIPP) medicine use and procurement…
Important information on drug data
The ‘One Drug Database’ project is underway, which will move all of our drug data into one place. This will provide a consistent, single source of information.
For years, we’ve had two sources of drug data – Master Data Replacement (MDR) for…